HPRT Company Press Release
Heartport Receives CE Mark Approval to Market PrecisionOP Beating Heart Bypass System in Europe
REDWOOD CITY, Calif.--(BW HealthWire)--March 16, 2000--Heartport, Inc. (Nasdaq:HPRT - news), announced today that the company received Conformite Europeene (CE) Mark approval for its PrecisionOP(tm)beating heart bypass system, enabling the company to market the system in Europe.
``Surgeons in the United States have been responding very favorably to the PrecisionOP system,' said Casey M. Tansey, Heartport's president and chief executive officer. ``Now, European surgeons will be able to use this technology to deliver the benefits of less invasive bypass surgery to more of their patients.'
Heartport began full-scale commercial introduction of the PrecisionOP system in the United States in the fourth quarter of 1999. The PrecisionOP system facilitates open-chest, off-pump, beating heart, multi-vessel CABG. It includes the disposable StillSite(tm) Stabilizer, a patented device designed for optimal stabilization of the target coronary arteries. It also includes the reusable OPTrac(tm) Retractor, which can be used in other open-chest procedures. The OPTrac has interchangeable, reusable retraction blades designed for varied patient anatomy and surgical approaches. Heartport also offers other disposables to be used with the PrecisionOP system, including suture stays and a heart retractor.
Cardiac surgeons who are currently using the PrecisionOP system have reported that it can be used easily in a wide variety of patients with excellent clinical results. They indicate that this system is more stable, giving them optimal access to and stabilization of targeted vessels at all locations, particularly those on the back wall of the heart. Because these vessels are often the hardest to reach and control, this system's attributes make it ideal for more complicated multi-vessel CABG operations.
Heartport, Inc., is a cardiovascular device company developing, manufacturing, and marketing products designed to make cardiac surgery less invasive for patients. The company's technologies allow surgeons to perform a wide range of less invasive open-chest and minimally invasive heart operations, including a full range of stopped-and beating-heart procedures.
Note: Except for the historical information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Actual events or results may differ materially due to factors set forth from time to time in Heartport's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
--------------------------------------------------------------------------------
Contact:
Heartport, Inc.
Media Contact:
Jim Weiss, 415/203-0328
or
Investor Contact:
Rebecca Kuhn, 650/482-4208
--------------------------------------------------------------------------------
More Quotes and News: Heartport Inc (NasdaqNM:HPRT - news)
Related News Categories: health care, medical/pharmaceutical
-------------------------------------------------------------------------------- |
